Somed Cr Sp. z o.o. sp.k.

Lodz 17 trials 4 recruiting

17 Registered trials

4 Currently recruiting

Organisation

Somed Cr Sp. z o.o. sp.k.

Location

Lodz, Poland

Identifier

ORG-100044205

Address

Ul. Podwislocze 46, 35-309, Poland

Departments

-
#3003: Rheumatology
#7803: Rheumatology
Clinical Trial
n.d.
N/A
NA
Somed CR
SOMED CR,ul.Piłsudskiego 9,90-368 Łódź is the name and address of the site where the pat.will attend

Clinical trials at this site (17)

Search interface

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Study of Enpatoran in Cutaneous Manifestations of Lupus With or Without Systemic Disease Pending

2025-523871-44-00 Cutaneous Manifestations of Lupus Erythematosus With or 5
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Recruiting

2022-500700-22-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-25
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
Cytisine for nicotine-containing electronic cigarette and tobacco cigarette cessation: a randomized placebo-controlled trial Recruiting

2023-504708-27-00 electronic cigarette cessation 5 2024-11-02
A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended

2024-516745-39-00 Cutaneous lupus erythematosus 4 2025-07-11
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Primary Sjögren’s Disease 5 2025-04-15
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended

2024-510584-37-00 Systemic Lupus Erythematosus 4 2024-10-22
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus Ended

2024-513031-24-00 Moderate-to-severe Systemic Lupus Erythematosus (SLE) 10 2021-10-22
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506256-25-00 Active Psoriatic Arthritis 5 2021-10-20
A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi… Ended

2022-501421-20-00 Gout with hyperuricemia 5 2024-04-09
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended

2023-503790-37-00 Post-Menopausal Osteoporosis 5 2024-01-09
A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in p… Ended

2022-502821-16-00 Knee Osteoarthritis 4 2023-09-01
A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended

2022-500445-24-00 Moderately to Severely Active Systemic Lupus Erythemato 5 2022-11-30
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and… Ended

2024-512417-41-00 Osteoporosis 5